INSM$148.75
$152.57
Chart
Performance
Key Stats
AI INSM Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyInsmed exhibits a strong thematic alignment with rare disease treatments and shows improving fundamentals, though its current valuation and near-term technicals suggest a balanced approach might be prudent for investors.
Thematic
Insmed is focused on rare and neglected diseases, a sector with significant unmet medical needs and strong tailwinds from advancements in biotechnology and personalized medicine.
Fundamental
Insmed is in a growth phase, with increasing revenue but still reporting net losses, which is typical for a biotech company investing heavily in clinical trials and drug development. Its balance sheet shows growing debt alongside growing assets.
Technical
The stock has shown strong upward momentum over the past year, trading above key moving averages. However, indicators like RSI suggest it might be approaching overbought levels, indicating potential for consolidation.
| Factor | Score |
|---|---|
| Rare Disease Focus | 95 |
| Biotechnology Innovation | 90 |
| Market Expansion | 85 |
| Regulatory Landscape | 90 |
| Healthcare Trends | 80 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 75 |
| Balance Sheet Health | 40 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 85 |
| Momentum | 70 |
| Moving Averages | 80 |
| Volume | 75 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Short-to-Medium Term Performance
The stock has shown positive performance across multiple short-term periods, with a 5-day return of 0.72%, a 1-month return of 1.75%, and a 6-month return of 33.35%.
Revenue Growth Trend
Revenue has shown an increasing trend from $188.46M in 2021 to $363.71M in 2024, indicating strong top-line growth potential.
Bearish Points (10)
Consistent Net Losses
The company has reported consistent net losses across all periods analyzed (TTM, annual, quarterly), with a significant net loss of -$913.77M in 2024.
High Price-to-Sales Ratio
The Price-to-Sales (P/S) ratio is significantly high, standing at 67.6 TTM and reaching up to 260.4 quarterly, indicating that the stock is very expensive relative to its revenue.
Calendar
August 2025
7
Next Earnings Date
H: $-1.18
A: $-1.31
L: $-1.47
H: 108.39M
A: 104.06M
L: 99.00M
Profile
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Seasonals
Price Target
115.44 USD
The 39 analysts offering 1 year price forecasts for INSM have a max estimate of 135.00 and a min estimate of 108.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Leader in rare pulmonary diseases (Cystic Fibrosis) and strong rare disease R&D, sharing a focus on chronic, debilitating conditions.
Weight: 95
A pure-play rare genetic disease company, sharing a core business model and market focus on orphan indications with INSM.
Weight: 92
Develops treatments for rare diseases, including genetic and neuromuscular disorders, operating in a similar niche as INSM.
Weight: 90
A pioneer in gene therapies for rare neuromuscular diseases (e.g., Duchenne Muscular Dystrophy), indicating a shared focus on advanced therapies for rare conditions.